| 315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort Y Kuboki, R Yaeger, MG Fakih, JH Strickler, T Masuishi, EJ Kim, ... Annals of Oncology 33, S680-S681, 2022 | 33 | 2022 |
| 434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p … M Fakih, GS Falchook, DS Hong, RD Yaeger, E Chan, O Mather, ... Annals of Oncology 32, S551, 2021 | 31 | 2021 |
| Obesity and pediatric drug development JD Vaughns, LS Conklin, Y Long, P Zheng, F Faruque, DJ Green, ... The Journal of Clinical Pharmacology 58 (5), 650-661, 2018 | 24 | 2018 |
| 45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort Y Kuboki, R Yaeger, M Fakih, JH Strickler, T Masuishi, EJH Kim, ... Annals of Oncology 33, S1445-S1446, 2022 | 18 | 2022 |
| Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial Y Kuboki, M Fakih, J Strickler, R Yaeger, T Masuishi, EJ Kim, CM Bestvina, ... Nature medicine, 1-6, 2024 | 12 | 2024 |
| Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase … DS Hong, Y Kuboki, JH Strickler, M Fakih, H Houssiau, TJ Price, E Elez, ... Journal of Clinical Oncology 41 (16_suppl), 3513-3513, 2023 | 11 | 2023 |
| Novel mechanisms of valproate hepatotoxicity: impaired Mrp2 trafficking and hepatocyte depolarization D Fu, P Cardona, H Ho, PB Watkins, KLR Brouwer Toxicological Sciences 171 (2), 431-442, 2019 | 10 | 2019 |
| Neonatal safety information reported to the FDA during drug development studies D Avant, G Baer, J Moore, P Zheng, A Sorbello, R Ariagno, L Yao, ... Therapeutic innovation & regulatory science 52 (1), 100-108, 2018 | 8 | 2018 |
| 444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated … T Masuishi, Y Kuboki, MG Fakih, JH Strickler, M Furqan, EJ Kim, ... Annals of Oncology 33, S737-S738, 2022 | 5 | 2022 |
| AN OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF SINGLE AND MULTIPLE DOSES OF RIFAMPIN ON THE PHARMACOKINETICS OF SOTORASIB (AMG 510) IN HEALTHY SUBJECTS. P Cardona, M Spring, J Purkis, O Mather, S Dutta, B Houk CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S31-S31, 2021 | 2 | 2021 |
| AN OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF SOTORASIB (AMG 510) ON DIGOXIN PHARMACOKINETICS IN HEALTHY SUBJECTS. P Cardona, M Spring, J Purkis, O Mather, S Dutta, B Houk CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S31-S31, 2021 | 2 | 2021 |
| AN OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF OMEPRAZOLE ON THE PHARMACOKINETICS OF SOTORASIB (AMG 510) IN HEALTHY SUBJECTS. P Cardona, M Simiens, J Purkis, O Mather, S Dutta, B Houk CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S31-S31, 2021 | 2 | 2021 |
| 92MO Sotorasib (Soto)+ panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib … T Masuishi, JH Strickler, JP Machiels, DS Hong, R Greil, E Chan, ... Annals of Oncology 34, S1505, 2023 | 1 | 2023 |
| 102. AAV9 Exclusively Targets the Juxtaglomerular Apparatus in the Adult Mouse Kidney After Intravenous Injection B Xiao, P Zheng, Z Yuan, C Qiao, J Li, X Xiao Molecular Therapy 23, S43, 2015 | 1 | 2015 |
| Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib P Cardona, S Dutta, B Houk Clinical Pharmacology in Drug Development, 2024 | | 2024 |
| Abstract CT264: Taking sotorasib with an acidic beverage improves sotorasib exposure for subjects on omeprazole N Strydom, P Cardona, M Spring, J Purkis, B Houk Cancer Research 83 (8_Supplement), CT264-CT264, 2023 | | 2023 |
| AN OPEN-LABEL STUDY TO ASSESS THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF SOTORASIB IN HEALTHY SUBJECTS. P Cardona, S Hutton, J Purkis, O Mather, S Dutta, B Houk CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S12-S12, 2022 | | 2022 |
| AN OPEN-LABEL STUDY TO EVALUATE THE DRUG-DRUG INTERACTION EFFECT OF ITRACONAZOLE, A STRONG CYP3A4 AND P-GP INHIBITOR, ON THE PHARMACOKINETICS OF SOTORASIB IN HEALTHY SUBJECTS. P Cardona, S Hutton, J Purkis, O Mather, S Dutta, B Houk CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S12-S12, 2022 | | 2022 |
| AN OPEN-LABEL STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY OF SOTORASIB ADMINISTERED AS TABLETS OR AS A WATER DISPERSION IN HEALTHY SUBJECTS. P Cardona, M Spring, J Purkis, O Mather, S Dutta, B Houk CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S11-S12, 2022 | | 2022 |
| Novel Mechanisms of Valproate Hepatotoxicity: Impaired Trafficking of Apical Transporters and Hepatocyte Depolarization D Fu, P Cardona, K Brouwer HEPATOLOGY 68, 432A-432A, 2018 | | 2018 |
